TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9807537

Group type: EXPERIMENTAL
Intervention: Health promotion-health protection intervention
Number of subjects: 2386

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2386
Study: 7658254

Group type: EXPERIMENTAL
Intervention: Four standardized rest periods each day
Number of subjects: 46
Study: 2506751

Group type: EXPERIMENTAL
Intervention: Low dose intravenous nitroglycerin
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study: 180175

Group type: EXPERIMENTAL
Intervention: Rhinovirus type 2
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 31833569

Group type: EXPERIMENTAL
Intervention: Spironolactone (≤50 mg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Doxazosin (control ≤16 mg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Beetroot juice (70 mL, ≤11 mmol nitrate)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Nitrate-depleted juice (placebo; 0 mmol nitrate)
Number of subjects: 100
Study: 28737971

Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate (FF; 100 μg)
Number of subjects: 16485

Group type: EXPERIMENTAL
Intervention: Vilanterol (VI; 25 μg)
Number of subjects: 16485

Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate and Vilanterol (FF/VI)
Number of subjects: 16485

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16485
Study: 27871548

Group type: EXPERIMENTAL
Intervention: Sevoflurane (group SEV)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Isoflurane (group ISO)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Sevoflurane (in vitro)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Isoflurane (in vitro)
Number of subjects: 46
Study: 24361787

Group type: EXPERIMENTAL
Intervention: Lymphadenectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: No lymphadenectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Node negative patients (≤65 years)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Node positive patients (≤65 years)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Node negative patients (>65 years)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Node positive patients (>65 years)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Obesity (BMI >30) in older patients
Number of subjects: 0
Study: 22526822

Group type: EXPERIMENTAL
Intervention: Difficulty in initiating sleep (DIS)
Number of subjects: 6510

Group type: EXPERIMENTAL
Intervention: Difficulty in maintaining sleep (DMS)
Number of subjects: 6510

Group type: EXPERIMENTAL
Intervention: Early morning awakening (EMA)
Number of subjects: 6510

Group type: EXPERIMENTAL
Intervention: Non-restorative sleep (NRS)
Number of subjects: 6510

Group type: EXPERIMENTAL
Intervention: Overall insomnia
Number of subjects: 6510

Group type: EXPERIMENTAL
Intervention: Sociodemographic and clinical correlates
Number of subjects: 6510

Group type: EXPERIMENTAL
Intervention: Age-related risks
Number of subjects: 6510

Group type: EXPERIMENTAL
Intervention: Psychiatric disorders
Number of subjects: 6510
Study: 20546495

Group type: EXPERIMENTAL
Intervention: Group ZP (fully anatomical technique)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Group ZC (traditional layering technique)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Group ZPC (cutback technique)
Number of subjects: 30
Study: 18988166

Group type: EXPERIMENTAL
Intervention: 1.25 mg intravitreal bevacizumab (IVB group)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Combination of 1.25 mg bevacizumab and 2 mg triamcinolone acetonide (IVB+IVT group)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Macular laser photocoagulation (MPC)
Number of subjects: 110
Study: 15965622

Group type: EXPERIMENTAL
Intervention: Prenatal care from health department clinics
Number of subjects: 1867

Group type: COMPARATOR
Intervention: Prenatal care from private physicians or HMOs
Number of subjects: 1867

Group type: COMPARATOR
Intervention: Prenatal care from hospital clinics
Number of subjects: 1867

Group type: COMPARATOR
Intervention: Prenatal care from other sites
Number of subjects: 1867

Group type: COMPARATOR
Intervention: Overall population
Number of subjects: 1867

Group type: COMPARATOR
Intervention: Private prenatal patients compared to health department prenatal clinic patients
Number of subjects: 1867
Study: 12059911

Group type: EXPERIMENTAL
Intervention: 1.0% sodium hypochlorite associated with 15% EDTAC
Number of subjects: 20

Group type: COMPARATOR
Intervention: 1.0% sodium hypochlorite alone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Distilled water
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 1.0% sodium hypochlorite and 15% EDTAC (not instrumented)
Number of subjects: 20
Study: 10530177

Group type: EXPERIMENTAL
Intervention: 0.05% NaF solution rinsing (n = 49)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: 1.66 mg NaF tablet (n = 51)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Toothpaste slurry brushing (n = 32)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Usual brushing (n = 32)
Number of subjects: 164
Study: 7862939

Group type: EXPERIMENTAL
Intervention: Nicotine gum (chewed for 4 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chronic smoking (smoked ad libitum for 2 days, then abstinent for 4 days, then resumed smoking for 2 days)
Number of subjects: 0
Study: 2757958

Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA) 5 mg/kg per day
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA) continued for up to 4 weeks after clinical clearance
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA)
Number of subjects: 17
Study: 4817159

Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test in the afternoon
Number of subjects: 31
Study: 31479045

Group type: EXPERIMENTAL
Intervention: Limited Sampling Strategies (LSS) with sampling at 0, 120, 180, and 240 minutes after the start of the second infusion (LSS15)
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Limited Sampling Strategies (LSS)
Number of subjects: 297

Group type: COMPARATOR
Intervention: Intensive Sampling Strategy (ISS)
Number of subjects: 297
Study: 31206973

Group type: EXPERIMENTAL
Intervention: Intensive treatment group
Number of subjects: 195

Group type: COMPARATOR
Intervention: Conventional treatment group
Number of subjects: 195
Study: 27780297

Group type: EXPERIMENTAL
Intervention: 2.5 mg Nazolam
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 5.0 mg Nazolam
Number of subjects: 16

Group type: COMPARATOR
Intervention: 2.5 mg intravenous midazolam
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Nazolam
Number of subjects: 16
Study: 25855760

Group type: COMPARATOR
Intervention: OAC (standard triple therapy)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: OA-OACM (hybrid therapy)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: OACM (10 day concomitant regimen)
Number of subjects: 300
Study: 24144653

Group type: EXPERIMENTAL
Intervention: Naltrexone sustained-release/bupropion sustained-release (NB)
Number of subjects: 505

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 505
Study: 21356537

Group type: EXPERIMENTAL
Intervention: 12 months of case management by district nurses for both older adults and informal caregivers
Number of subjects: 99

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 99
Study: 18821000

Group type: EXPERIMENTAL
Intervention: Intervention activities (presentations at organizations)
Number of subjects: 591

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 591

Group type: EXPERIMENTAL
Intervention: Awareness of or participation in intervention activities
Number of subjects: 591

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 591
Study: 17701410

Group type: EXPERIMENTAL
Intervention: Positron emission tomography (PET) scanning
Number of subjects: 186
Study: 15253920

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training
Number of subjects: 301

Group type: COMPARATOR
Intervention: No training (control)
Number of subjects: 301
Study: 11547370

Group type: EXPERIMENTAL
Intervention: 4-step lateral release sequence (PCL, IT band, PT/LCL, biceps femoris tendon)
Number of subjects: 14

Group type: COMPARATOR
Intervention: 5-step lateral release sequence (PCL, posterolateral capsule, IT band, PT, LCL)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Both sequences (4-step and 5-step)
Number of subjects: 14
Study: 9565144

Group type: EXPERIMENTAL
Intervention: pFSH
Number of subjects: 20

Group type: COMPARATOR
Intervention: GnRH-a plus pFSH
Number of subjects: 20
Study: 7800954

Group type: EXPERIMENTAL
Intervention: Twice daily oral theophylline (800 mg/day)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Twice daily inhaled budesonide (0.8 mg/day)
Number of subjects: 8
Study: 31254097

Group type: EXPERIMENTAL
Intervention: Early discharge (≤ 48 hours)
Number of subjects: 311

Group type: COMPARATOR
Intervention: Inpatient management (> 48 hours)
Number of subjects: 311
Study: 29546857

Group type: EXPERIMENTAL
Intervention: H1-coil rTMS as an add-on to stable pharmacotherapy
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Figure-8-coil rTMS as an add-on to stable pharmacotherapy
Number of subjects: 228

Group type: COMPARATOR
Intervention: Stable pharmacotherapy alone
Number of subjects: 228
Study: 26662632

Group type: EXPERIMENTAL
Intervention: Aprepitant
Number of subjects: 324

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 324
Study: 25911823

Group type: EXPERIMENTAL
Intervention: Modified Ganmai Dazao decoction
Number of subjects: 86

Group type: COMPARATOR
Intervention: Deanxit (Control)
Number of subjects: 86
Study: 22913800

Group type: EXPERIMENTAL
Intervention: Perampanel (titrated to a maximum of 12 mg/day over 12 weeks, maintained for up to 424 weeks)
Number of subjects: 138
Study: 20552369

Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy (LA)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Open appendectomy (OA)
Number of subjects: 147
Study: 18435373

Group type: EXPERIMENTAL
Intervention: Adper Scotchbond 2 (SB)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond (SE)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Adper Scotchbond MP (MP)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Adper Prompt L-Pop (LP)
Number of subjects: 40
Study: 16490027

Group type: EXPERIMENTAL
Intervention: Cavernosal arteries diameter assessment
Number of subjects: 212

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Brachial arteries assessment
Number of subjects: 212
Study: 14655913

Group type: EXPERIMENTAL
Intervention: Cabergoline (upward titration from 0.5 mg to 2 mg in a single evening dose)
Number of subjects: 12
Study: 10731495

Group type: EXPERIMENTAL
Intervention: High-glycemic-index (high-GI) diet
Number of subjects: 10

Group type: COMPARATOR
Intervention: Low-glycemic-index (low-GI) diet
Number of subjects: 10
Study: 9363043

Group type: EXPERIMENTAL
Intervention: abecarnil
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: alprazolam
Number of subjects: 180

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 180
Study: 1489150

Group type: EXPERIMENTAL
Intervention: 2% lidocaine aerosol
Number of subjects: 38

Group type: COMPARATOR
Intervention: Saline aerosol (control)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 4% lidocaine aerosol
Number of subjects: 38
Study: 3888102

Group type: EXPERIMENTAL
Intervention: Ribavirin small-particle aerosol treatment (2.4 g over 42 h during 68 h of hospitalization)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Ribavirin aerosol treatment
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 38
Study: 31574097

Group type: EXPERIMENTAL
Intervention: Football group (FG) - 6 months of free-of-charge football training twice weekly
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Football group (FG)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Usual care group (UG)
Number of subjects: 214
Study: 30202187

Group type: EXPERIMENTAL
Intervention: Community Engagement and Planning (CEP)
Number of subjects: 1013

Group type: COMPARATOR
Intervention: Resources for Services (RS)
Number of subjects: 1013
Study: 26204844

Group type: EXPERIMENTAL
Intervention: Strontium ranelate (SrR) 2 g daily
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 24247211

Group type: EXPERIMENTAL
Intervention: Fructose (40g)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Glucose (40g)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Inulin (40g)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Glucose + Fructose (40g each)
Number of subjects: 16
Study: 22930293

Group type: EXPERIMENTAL
Intervention: Clindamycin vaginal cream (CVC) for three days
Number of subjects: 199

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Clindamycin vaginal cream (CVC) additional seven-day course
Number of subjects: 199

Group type: COMPARATOR
Intervention: Placebo additional seven-day course
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Clindamycin vaginal cream (CVC) additional treatment
Number of subjects: 199

Group type: COMPARATOR
Intervention: Placebo additional treatment
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Clindamycin vaginal cream (CVC)
Number of subjects: 199
Study: 19429844

Group type: EXPERIMENTAL
Intervention: Anxiety condition (induced by pictures from the International Affective Picture System and in sensu exposure to individual anxiety‐provoking situations)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Nonanxiety condition (neutral condition)
Number of subjects: 90
Study: 17394957

Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg 12 hours before PCI, with a further 40 mg preprocedure dose)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study: 16227994

Group type: EXPERIMENTAL
Intervention: Hemoglobin S variant and alpha(+)-thalassemia inherited together
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hemoglobin S variant inherited alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alpha(+)-thalassemia inherited alone
Number of subjects: 0
Study: 11861723

Group type: EXPERIMENTAL
Intervention: Patellar resurfacing
Number of subjects: 220

Group type: COMPARATOR
Intervention: No patellar resurfacing
Number of subjects: 220
Study: 10206312

Group type: EXPERIMENTAL
Intervention: High energy intake (> 12,013 kJ)
Number of subjects: 1378

Group type: COMPARATOR
Intervention: Low energy intake (< 7004 kJ)
Number of subjects: 1378

Group type: EXPERIMENTAL
Intervention: Tall girls (> 148.6 cm)
Number of subjects: 1378

Group type: COMPARATOR
Intervention: Short girls (< 135.9 cm)
Number of subjects: 1378

Group type: EXPERIMENTAL
Intervention: High Quetelet's index (QI, kg m(‐2)) (> 20.7)
Number of subjects: 1378

Group type: COMPARATOR
Intervention: Low Quetelet's index (QI, kg m(‐2)) (< 16.1)
Number of subjects: 1378

Group type: EXPERIMENTAL
Intervention: Hispanic, Asian/Pacific Island and African‐American girls
Number of subjects: 1378
Study: 7606182

Group type: EXPERIMENTAL
Intervention: 100 units of botulinum A toxin
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Botulinum toxin injections
Number of subjects: 23
Study: 2350209

Group type: EXPERIMENTAL
Intervention: Cocaine hydrochloride (40 mg intravenously)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 8
Study: 111274

Group type: EXPERIMENTAL
Intervention: Clorgyline treatment for 4 weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Pargyline treatment
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Clorgyline in crossover study
Number of subjects: 16

Group type: COMPARATOR
Intervention: Pargyline in crossover study
Number of subjects: 16
Study: 31863189

Group type: EXPERIMENTAL
Intervention: Diphenhydramine 30 mg intravenously after induction of general anesthesia
Number of subjects: 96

Group type: COMPARATOR
Intervention: Normal saline 2 ml
Number of subjects: 96
Study: 30504445

Group type: EXPERIMENTAL
Intervention: Rituximab (1000 mg single infusion)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 28879445

Group type: EXPERIMENTAL
Intervention: Osteoporosis and You knowledge scale
Number of subjects: 7749

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 7749
Study: 25533540

Group type: EXPERIMENTAL
Intervention: Pramipexole (PPX) 0.25 mg to 0.75 mg, taken 2-3 hours before bedtime for 12 weeks
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Pramipexole (PPX)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study: 23676253

Group type: EXPERIMENTAL
Intervention: 40 IU intranasal oxytocin
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 21833787

Group type: EXPERIMENTAL
Intervention: ACT Parents Raising Safe Kids program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard community‐based support services
Number of subjects: 0
Study: 19415120

Group type: EXPERIMENTAL
Intervention: MB-artesunate (AS)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: MB-amodiaquine (AQ)
Number of subjects: 180

Group type: COMPARATOR
Intervention: AS-amodiaquine (AQ)
Number of subjects: 180
Study: 17268766

Group type: EXPERIMENTAL
Intervention: Intravenous anesthesia
Number of subjects: 86

Group type: COMPARATOR
Intervention: Epidural anesthesia
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 86
Study: 15354727

Group type: EXPERIMENTAL
Intervention: SUNY4001 (adenosine)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Exercise (ergometer)
Number of subjects: 41
Study: 11146393

Group type: EXPERIMENTAL
Intervention: bivalent HAV/HBV vaccine
Number of subjects: 39

Group type: COMPARATOR
Intervention: HBV vaccine alone
Number of subjects: 39
Study: 9557092

Group type: EXPERIMENTAL
Intervention: Antibiotics and Gamma‐Venin P
Number of subjects: 30

Group type: COMPARATOR
Intervention: Antibiotics only
Number of subjects: 30
Study: 8354633

Group type: EXPERIMENTAL
Intervention: AZT treatment
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 67
Study: 3524509

Group type: EXPERIMENTAL
Intervention: D-phenylalanine (DPA) 250 mg orally four times a day for four weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Lactose (placebo) orally four times a day for four weeks
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: D-phenylalanine (DPA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Lactose (placebo)
Number of subjects: 30
Study: 30466144

Group type: EXPERIMENTAL
Intervention: Soap bubble protocol
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 74
Study: 29128692

Group type: EXPERIMENTAL
Intervention: Aspirin 975 mg tid and omeprazole 20 mg od
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 26155004

Group type: EXPERIMENTAL
Intervention: 2% papain gel
Number of subjects: 18

Group type: COMPARATOR
Intervention: 2% carboxymethyl cellulose gel
Number of subjects: 18
Study: 24231646

Group type: EXPERIMENTAL
Intervention: Tacrolimus/Mycophenolate Mofetil (Tac/MMF)
Number of subjects: 307

Group type: COMPARATOR
Intervention: Cyclosporine/Azathioprine (CsA/AZA)
Number of subjects: 307
Study: 21814138

Group type: EXPERIMENTAL
Intervention: recombinant GH (rGH) administration, 6 IU daily
Number of subjects: 12
Study: 19487903

Group type: EXPERIMENTAL
Intervention: Nonnucleoside reverse transcriptase inhibitor (NNRTI) + protease inhibitor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Classical nucleoside reverse transcriptase inhibitor (NRTI) based regimen
Number of subjects: 0
Study: 16877196

Group type: EXPERIMENTAL
Intervention: Intervention to promote motivation for weight loss
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intervention fidelity criteria
Number of subjects: 0
Study: 15488341

Group type: EXPERIMENTAL
Intervention: Oral methylphenidate (MPH) 0.5 mg/kg
Number of subjects: 11
Study: 11681631

Group type: EXPERIMENTAL
Intervention: High-monounsaturated fatty acids (MUFA) diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control diet (not specified)
Number of subjects: 0
Study: 9475306

Group type: EXPERIMENTAL
Intervention: Rice oral rehydration solution (ORS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glucose oral rehydration solution (ORS)
Number of subjects: 0
Study: 7524313

Group type: EXPERIMENTAL
Intervention: Fresh frozen plasma (FFP) 20 ml/kg
Number of subjects: 8
Study: 2856598

Group type: EXPERIMENTAL
Intervention: Pirprofen administered by iontophoresis
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Lysine soluble aspirin administered by iontophoresis
Number of subjects: 80
Study: 31758375

Group type: EXPERIMENTAL
Intervention: 1000 IU/day of vitamin D for 10 days
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 4000 IU/day of vitamin D for 10 days
Number of subjects: 20
Study: 29659658

Group type: EXPERIMENTAL
Intervention: 8-week low-fat diet (<20% of energy from fat)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: 8-week high-fat diet (>35% of energy from fat)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Low-fat diet (n=32)
Number of subjects: 88

Group type: COMPARATOR
Intervention: High-fat diet (n=35)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Heritability of baseline FT rank
Number of subjects: 88
Study: 28954802

Group type: EXPERIMENTAL
Intervention: Immediate discharge (n=53)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Management in an observation unit with stress testing (n=52)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Both groups (n=105)
Number of subjects: 105
Study: 25672646

Group type: EXPERIMENTAL
Intervention: Bowel preparation (n = 60)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control group (n = 61)
Number of subjects: 121
Study: 23534020

Group type: EXPERIMENTAL
Intervention: MDPB-containing adhesive system (Clearfil Protect Bond)
Number of subjects: 40

Group type: COMPARATOR
Intervention: MDPB-free self-etching adhesive system (Clearfil SE Bond)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: MDPB-containing self-etching primer with fluoride-free bonding agent
Number of subjects: 40

Group type: COMPARATOR
Intervention: MDPB-free self-etching primer with fluoride-containing bonding agent
Number of subjects: 40

Group type: COMPARATOR
Intervention: Three-step etch-and-rinse adhesive system (Adper Scotchbond Multi Purpose)
Number of subjects: 40